Abstract
Purpose
To compare the intraocular pressure (IOP) reduction over 24 h achieved with tafluprost (0.0015%) with that achieved with latanoprost (0.005%).
Methods
Twenty-seven healthy volunteers were studied. After a 24-h IOP baseline measurement was taken, one ophthalmic solution was applied to the right eye daily for 7 days. The drug was then withdrawn for 2 weeks. The other agent was then applied to the left eye in the same manner. IOP was measured every 3 h for 24 h on the seventh day of treatment.
Results
The 24-h IOP after 7 days’ treatment with latanoprost decreased from 11.5 mmHg at baseline to 9.7 mmHg (−1.8 mmHg) and that with tafluprost from 11.8 to 9.8 mmHg (−1.9 mmHg). Tafluprost was statistically more effective after 24 h (P = 0.007; paired t test). The number of subjects with a 24-h mean IOP reduction of <10% was 8/27 (29.6%) with latanoprost versus 4/27 (14.8%) with tafluprost. The incidence of conjunctival hyperemia with latanoprost was 4/27 (14.8%) and that with tafluprost was 8/27 (29.6%).
Conclusion
The overall efficacies of the two agents were not different, but tafluprost was associated with a greater reduction in IOP at 24 h after administration. Tafluprost showed a higher rate of conjunctival hyperemia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138–147.
Mishima HK, Kiuchi Y, Takamatsu M, et al. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 1997;41Suppl 2:S139–S144.
Ikeda Y, Mori K, Ishibashi T, et al. Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma. J Ocul Pharmacol Ther 2008;24:230–234.
Ishibashi S, Hirose N, Tawara A, et al. Effect of latanoprost on the diurnal variations in the intraocular and ocular perfusion pressure in normal tension glaucoma. J Glaucoma 2006;15:354–357.
Kashiwagi K, Tsumura T, Tsukahara S. Long-term effects of latanoprost monotherapy on intraocular pressure in Japanese glaucoma patients. J Glaucoma 2008;17:662–666.
Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol 2009;53:18–23.
Thelen U, Weiler W, Kirchhoff E, et al. Clinical experience in the treatment of normal tension glaucoma with latanoprost in Germany. J Ocul Pharmacol Ther 2007;23:311–313.
Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull 2003;26:1691–1695.
Ota T, Murata H, Sugimoto E, et al. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest Ophthalmol Vis Sci 2005;46:2006–2011.
Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 2004;78:767–776.
Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther 2007;23:359–365.
Konstas AG, Karabatsas CH, Lallos N, et al. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. Ophthalmology 2005;112:603–608.
Konstas AG, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007;114:653–657.
Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma 2007;16:352–357.
Quaranta L, Pizzolante T, Riva I, et al. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol 2008;92:1227–1231.
Ang GS, Kersey JP, Shepstone L, et al. The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial. Br J Ophthalmol 2008;92:1129–1133.
Camras CB, Hedman K; US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 2003;12:466–469.
Honrubia F, García-Sánchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol 2009;93:316–321.
Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma 2008;17:667–673.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mochizuki, H., Itakura, H., Yokoyama, T. et al. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. Jpn J Ophthalmol 54, 286–290 (2010). https://doi.org/10.1007/s10384-010-0828-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-010-0828-7